Skip to main content
SpringerLink
Log in

Quality of Life in Parkinson’s Disease

  • Chapter
  • First Online:
Movement Disorders Curricula

  • 1388 Accesses

Abstract

Quality of life is an important patient-reported outcome, and it should be used as an additional endpoint in clinical practice, research studies, and clinical trials. There are several general and PD-specific QoL measures recommended to assess QoL in PD. Motor and non-motor symptoms have a great impact on patients’ QoL, and the contribution of the latter can outweigh the former. Previous studies have documented the positive effect of surgical and pharmaceutical treatment options on QoL. The effect of the following PD treatment options on QoL is described: levodopa (as monotherapy or with tolcapone or entacapone), dopamine agonists (rotigotine, pramipexole, cabergoline, ropinirole, pergolide, piribedil, and bromocriptine), monoamine oxidase inhibitors (selegiline, rasagiline, and safinamide), rivastigmine, treatments for advanced PD (surgery, duodopa, and apomorphine), and non-pharmacological treatments. Concerning newer pharmacological options, several studies provide evidence for the positive effect of duodopa on PD patient’s QoL. However, there is a need for randomized controlled trials that assess the effect of apomorphine on QoL. Exercise therapy seems beneficial, but there is inconclusive evidence about the effect of other non-pharmacological therapies in QoL.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 149.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 149.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

15D-QoL:

15-dimensional quality of life instrument

COMT:

Catechol-O-methyltransferase

EQ-5D-3L:

EQ-5D questionnaire with 3 levels of severity

EQ-5D-5L:

EQ-5D questionnaire with 5 levels of severity

MDS:

Movement Disorders Society

NHP:

Nottingham health profile

NMS:

Non-motor symptoms

PD:

Parkinson’s disease

PDQ-8:

8-item Parkinson’s disease questionnaire

PDQ-39:

39-item Parkinson’s disease questionnaire

PDQL:

Parkinson’s disease quality of life questionnaire

PIMS:

Parkinson’s impact scale

PRO:

Patient-reported outcome

QoL:

Quality of life

SCOPA-PS:

Scales for outcomes in Parkinson’s disease-psychosocial

SF-36:

36-item short-form health survey

SIP:

Sickness impact profile

References

  1. World Health Organization Division of Mental Health and Prevention of Substance. WHOQOL : measuring quality of life [Internet]. 1997. http://apps.who.int/iris/handle/10665/63482.

  2. Ware JEJ. The status of health assessment 1994. Annu Rev Public Health. 1995;16:327–54.

    Article  PubMed  Google Scholar 

  3. Martinez-Martin P, Jeukens-Visser M, Lyons KE, Rodriguez-Blazquez C, Selai C, Siderowf A, et al. Health-related quality-of-life scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2011;26(13):2371–80.

    Article  PubMed  Google Scholar 

  4. EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.

    Article  Google Scholar 

  5. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Alvarado-Bolaños A, Cervantes-Arriaga A, Rodríguez-Violante M, Llorens-Arenas R, Calderón-Fajardo H, Millán-Cepeda R, et al. Convergent validation of EQ-5D-5L in patients with Parkinson’s disease. J Neurol Sci. 2015;358(1–2):53–7.

    Article  PubMed  Google Scholar 

  7. García-Gordillo MÁ, del Pozo-Cruz B, Adsuar JC, Sánchez-Martínez FI, Abellán-Perpiñán JM. Validation and comparison of 15-D and EQ-5D-5L instruments in a Spanish Parkinson’s disease population sample. Qual Life Res. 2014;23(4):1315–26.

    Article  PubMed  Google Scholar 

  8. Hunt SM, McEwen J, McKenna SP. Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract. 1985;35(273):185–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Ware JEJ, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.

    Article  PubMed  Google Scholar 

  10. Ware JJ, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–33.

    Article  PubMed  Google Scholar 

  11. Turner-Bowker DM, Bayliss MS, Ware JEJ, Kosinski M. Usefulness of the SF-8 Health Survey for comparing the impact of migraine and other conditions. Qual Life Res. 2003;12(8):1003–12.

    Article  PubMed  Google Scholar 

  12. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The sickness impact profile: development and final revision of a health status measure. Med Care. 1981;19(8):787–805.

    Article  CAS  PubMed  Google Scholar 

  13. Post MW, Gerritsen J, Diederikst JP, DeWittet LP. Measuring health status of people who are wheelchair-dependent: validity of the Sickness Impact Profile 68 and the Nottingham Health Profile. Disabil Rehabil. 2001;23(6):245–53.

    Article  CAS  PubMed  Google Scholar 

  14. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res. 1995;4(3):241–8.

    Article  CAS  PubMed  Google Scholar 

  15. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The PDQ-8: development and validation of a short-form Parkinson’s disease Questionnaire. Psychol Health. 1997;12(6):805–14.

    Google Scholar 

  16. de Boer AG, Wijker W, Speelman JD, de Haes JC. Quality of life in patients with Parkinson’s disease: development of a questionnaire. J Neurol Neurosurg Psychiatry. 1996;61(1):70–4.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Damiano AM, Snyder C, Strausser B, Willian MK. A review of health-related quality-of-life concepts and measures for Parkinson’s disease. Qual Life Res. 1999;8(3):235–43.

    Article  CAS  PubMed  Google Scholar 

  18. Calne S, Schulzer M, Mak E, Guyette C, Rohs G, Hatchard S, et al. Validating a quality of life rating scale for idiopathic parkinsonism: Parkinson’s Impact Scale (PIMS). Parkinsonism Relat Disord. 1996;2(2):55–61.

    Article  CAS  PubMed  Google Scholar 

  19. Schulzer M, Mak E, Calne SM. The psychometric properties of the Parkinson’s Impact Scale (PIMS) as a measure of quality of life in Parkinson’s disease. Parkinsonism Relat Disord. 2003;9(5):291–4.

    Article  PubMed  Google Scholar 

  20. Marinus J, Visser M, Martínez-Martín P, van Hilten JJ, Stiggelbout AM. A short psychosocial questionnaire for patients with Parkinson’s disease: the SCOPA-PS. J Clin Epidemiol. 2003;56(1):61–7.

    Article  PubMed  Google Scholar 

  21. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry. 2000;69(3):308–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Martínez-Martin P, Carod-Artal FJ, da Silveira Ribeiro L, Ziomkowski S, Vargas AP, Kummer W, et al. Longitudinal psychometric attributes, responsiveness, and importance of change: an approach using the SCOPA-psychosocial questionnaire. Mov Disord. 2008;23(11):1516–23.

    Article  PubMed  Google Scholar 

  23. Schrag A, Spottke A, Quinn NP, Dodel R. Comparative responsiveness of Parkinson’s disease scales to change over time. Mov Disord. 2009;24(6):813–8.

    Article  PubMed  Google Scholar 

  24. Karlsen KH, Tandberg E, Arsland D, Larsen JP. Health related quality of life in Parkinson’s disease: a prospective longitudinal study. J Neurol Neurosurg Psychiatry. 2000;69(5):584–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Lang AE. Predictors of deterioration in health-related quality of life in Parkinson’s disease: results from the DATATOP trial. Mov Disord. 2008;23(5):653–9; quiz 776.

    Article  PubMed  Google Scholar 

  26. Reuther M, Spottke EA, Klotsche J, Riedel O, Peter H, Berger K, et al. Assessing health-related quality of life in patients with Parkinson’s disease in a prospective longitudinal study. Parkinsonism Relat Disord. 2007;13(2):108–14.

    Article  CAS  PubMed  Google Scholar 

  27. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson’s disease on the quality of life. Mov Disord. 2005;20(2):224–30.

    Article  PubMed  Google Scholar 

  28. Rahman S, Griffin HJ, Quinn NP, Jahanshahi M. Quality of life in Parkinson’s disease: the relative importance of the symptoms. Mov Disord. 2008;23(10):1428–34.

    Article  PubMed  Google Scholar 

  29. Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24(11):1641–9.

    Article  PubMed  Google Scholar 

  30. Leonardi M, Raggi A, Pagani M, Carella F, Soliveri P, Albanese A, et al. Relationships between disability, quality of life and prevalence of nonmotor symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(1):35–9.

    Article  PubMed  Google Scholar 

  31. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord. 2007;22(13):1901–11.

    Article  PubMed  Google Scholar 

  32. Martinez-Martin P, Rodriguez-Blazquez C, Abe K, Bhattacharyya KB, Bloem BR, Carod-Artal FJ, et al. International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology. 2009;73(19):1584–91.

    Article  CAS  PubMed  Google Scholar 

  33. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord. 2011;26(3):399–406.

    Article  PubMed  Google Scholar 

  34. Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ. Quality of life and burden in caregivers for patients with Parkinson’s disease: concepts, assessment and related factors. Expert Rev Pharmacoecon Outcomes Res. 2012;12(2):221–30.

    Article  PubMed  Google Scholar 

  35. Martinez-Martin P, Deuschl G. Effect of medical and surgical interventions on health-related quality of life in Parkinson’s disease. Mov Disord. 2007;22(6):757–65.

    Article  PubMed  Google Scholar 

  36. Gallagher DA, Schrag A. Impact of newer pharmacological treatments on quality of life in patients with Parkinson’s disease. CNS Drugs. 2008;22(7):563–86.

    Article  CAS  PubMed  Google Scholar 

  37. Iaconi AI, Zimmerman MA, Kulkarni AS, Balkrishnan R. Outcomes associated with pharmacologic treatments in Parkinson’s disease: a review of recent literature. Expert Opin Pharmacother. 2008;9(2):163–74.

    Article  CAS  PubMed  Google Scholar 

  38. Tan SB, Williams AF, Kelly D. Effectiveness of multidisciplinary interventions to improve the quality of life for people with Parkinson’s disease: a systematic review. Int J Nurs Stud. 2014;51(1):166–74.

    Article  PubMed  Google Scholar 

  39. Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, Kurtis MM. Impact of pharmacotherapy on quality of life in patients with Parkinson’s disease. CNS Drugs. 2015;29(5):397–413.

    Article  CAS  PubMed  Google Scholar 

  40. Luquin MR, García-Ruiz PJ, Martí MJ, Rojo A, Vela L, Grandas FJ, et al. Levodopa in the treatment of Parkinson’s disease: myths and realties. Rev Neurol. 2012;55(11):669–88.

    PubMed  Google Scholar 

  41. Hauser RA, Hsu A, Kell S, Espay AJ, Sethi K, Stacy M, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol. 2013;12(4):346–56.

    Article  CAS  PubMed  Google Scholar 

  42. Pahwa R, Lyons KE, Hauser RA, Fahn S, Jankovic J, Pourcher E, et al. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson’s disease. Parkinsonism Relat Disord. 2014;20(2):142–8.

    Article  PubMed  Google Scholar 

  43. Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141–9.

    Article  CAS  PubMed  Google Scholar 

  44. Encarnacion EV, Hauser RA. Levodopa-induced dyskinesias in Parkinson’s disease: etiology, impact on quality of life, and treatments. Eur Neurol. 2008;60(2):57–66.

    Article  CAS  PubMed  Google Scholar 

  45. Koller W, Lees A, Doder M, Hely M, Tolcapone/Pergolide Study Group. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson’s disease patients with motor fluctuations. Mov Disord. 2001;16(5):858–66.

    Article  CAS  PubMed  Google Scholar 

  46. Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, Pedder S. Tolcapone improves motor function in parkinsonian patients with the «wearing-off» phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology. 1997;49(4):1066–71.

    Article  CAS  PubMed  Google Scholar 

  47. Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the «wearing off» phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry. 1997;63(4):421–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Adler CH, Singer C, O’Brien C, Hauser RA, Lew MF, Marek KL, et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol. 1998;55(8):1089–95.

    Article  CAS  PubMed  Google Scholar 

  49. Welsh MD, Dorflinger E, Chernik D, Waters C. Illness impact and adjustment to Parkinson’s disease: before and after treatment with tolcapone. Mov Disord. 2000;15(3):497–502.

    Article  CAS  PubMed  Google Scholar 

  50. Grandas F, Hernández B, PRACTICOMT Study Group. Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson’s disease patients: the effects of an early therapeutic intervention. Eur J Neurol. 2007;14(3):282–9.

    Article  CAS  PubMed  Google Scholar 

  51. Reichmann H, Boas J, Macmahon D, Myllyla V, Hakala A, Reinikainen K, et al. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand. 2005;111(1):21–8.

    Article  CAS  PubMed  Google Scholar 

  52. Deuschl G, Vaitkus A, Fox G-C, Roscher T, Schremmer D, Gordin A, et al. Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off. Mov Disord. 2007;22(11):1550–5.

    Article  PubMed  Google Scholar 

  53. Tolosa E, Hernández B, Linazasoro G, López-Lozano JJ, Mir P, Marey J, et al. Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson’s disease experiencing mild wearing-off: a randomised, double-blind trial. J Neural Transm. 2014;121(4):357–66.

    Article  CAS  PubMed  Google Scholar 

  54. Martinez-Martin P, Kurtis MM. Systematic review of the effect of dopamine receptor agonists on patient health-related quality of life. Parkinsonism Relat Disord. 2009;15 Suppl 4:S58–64.

    Article  PubMed  Google Scholar 

  55. Jankovic J, Watts RL, Martin W, Boroojerdi B, SP 512 Rotigotine Transdermal System Clinical Study Group. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol. 2007;64(5):676–82.

    Article  PubMed  Google Scholar 

  56. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007;6(6):513–20.

    Article  CAS  PubMed  Google Scholar 

  57. Ghys L, Surmann E, Whitesides J, Boroojerdi B. Effect of rotigotine on sleep and quality of life in Parkinson’s disease patients: post hoc analysis of RECOVER patients who were symptomatic at baseline. Expert Opin Pharmacother. 2011;12(13):1985–98.

    Article  CAS  PubMed  Google Scholar 

  58. Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, et al. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26(1):90–9.

    Article  PubMed  Google Scholar 

  59. Antonini A, Bauer L, Dohin E, Oertel WH, Rascol O, Reichmann H, et al. Effects of rotigotine transdermal patch in patients with Parkinson’s disease presenting with non-motor symptoms – results of a double-blind, randomized, placebo-controlled trial. Eur J Neurol. 2015;22(10):1400–7.

    Article  CAS  PubMed  Google Scholar 

  60. Lyons KE, Pahwa R. Outcomes of rotigotine clinical trials: effects on motor and nonmotor symptoms of Parkinson’s disease. Neurol Clin. 2013;31(3 Suppl):S51–9.

    Article  PubMed  Google Scholar 

  61. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA. 2000;284(15):1931–8.

    Article  Google Scholar 

  62. Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61(7):1044–53.

    PubMed  Google Scholar 

  63. Noyes K, Dick AW, Holloway RG, Parkinson Study Group. Pramipexole versus levodopa in patients with early Parkinson’s disease: effect on generic and disease-specific quality of life. Value Health. 2006;9(1):28–38.

    Article  PubMed  Google Scholar 

  64. Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J Neurol. 2006;253(5):601–7.

    Article  CAS  PubMed  Google Scholar 

  65. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. International Pramipexole-Bromocriptine Study Group. Neurology. 1997;49(4):1060–5.

    Article  CAS  PubMed  Google Scholar 

  66. Linazasoro G, Spanish Dopamine Agonists Study Group. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease. Clin Neuropharmacol. 2008;31(1):19–24.

    Article  CAS  PubMed  Google Scholar 

  67. Baas HK, Schueler P. Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson’s disease. Eur Neurol. 2001;46 Suppl 1:18–23.

    Article  CAS  PubMed  Google Scholar 

  68. Odin P, Oehlwein C, Storch A, Polzer U, Werner G, Renner R, et al. Efficacy and safety of high-dose cabergoline in Parkinson’s disease. Acta Neurol Scand. 2006;113(1):18–24.

    Article  CAS  PubMed  Google Scholar 

  69. Takanashi M, Shimo Y, Hatano T, Oyama G, Hattori N. Efficacy and safety of a once-daily extended-release formulation of pramipexole switched from an immediate-release formulation in patients with advanced Parkinson’s disease: results from an open-label study. Drug Res (Stuttg). 2013;63(12):639–43.

    Article  CAS  Google Scholar 

  70. Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, et al. Ten-year follow-up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord. 2007;22(16):2409–17.

    Article  PubMed  Google Scholar 

  71. Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 2007;68(14):1108–15.

    Article  CAS  PubMed  Google Scholar 

  72. Thobois S, Lhommée E, Klinger H, Ardouin C, Schmitt E, Bichon A, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain. 2013;136(5):1568–77.

    Article  PubMed  Google Scholar 

  73. Rascol O, Dubois B, Caldas AC, Senn S, Del Signore S, Lees A, et al. Early piribedil monotherapy of Parkinson’s disease: a planned seven-month report of the REGAIN study. Mov Disord. 2006;21(12):2110–5.

    Article  PubMed  Google Scholar 

  74. Salazar Tortolero G, Wix Ramos R, Salazar Aladrén P, Jiménez León JC. The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson’s disease: a nine month follow up. Rev Neurol. 2004;38(8):715–9.

    CAS  PubMed  Google Scholar 

  75. Evidente VGH, Esteban RP, Domingo FM, Carbajal LO, Parazo MA. Piribedil as an adjunct to levodopa in advanced Parkinson’s disease: the Asian experience. Parkinsonism Relat Disord. 2003;10(2):117–21.

    Article  PubMed  Google Scholar 

  76. Suwantamee J, Nidhinandana S, Srisuwananukorn S, Laptikultham S, Pisarnpong A, Chankrachang S, et al. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson’s disease: a 6-month open study. J Med Assoc Thai. 2004;87(11):1293–300.

    PubMed  Google Scholar 

  77. Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology. 2008;71(7):474–80.

    Article  CAS  PubMed  Google Scholar 

  78. Shannon KM. Long-term outcome in Parkinson disease: no advantage to initiating therapy with dopamine agonists. Nat Clin Pract Neurol. 2008;4(11):590–1.

    Article  CAS  PubMed  Google Scholar 

  79. Reichmann H, Jost WH. Efficacy and tolerability of rasagiline in daily clinical use – a post-marketing observational study in patients with Parkinson’s disease. Eur J Neurol. 2010;17(9):1164–71.

    Article  CAS  PubMed  Google Scholar 

  80. Jost WH, Klasser M, Reichmann H. Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment. Fortschr Neurol Psychiatr. 2008;76(10):594–9.

    Article  CAS  PubMed  Google Scholar 

  81. Müller T, Hoffmann JA, Dimpfel W, Oehlwein C. Switch from selegiline to rasagiline is beneficial in patients with Parkinson’s disease. J Neural Transm. 2013;120(5):761–5.

    Article  PubMed  CAS  Google Scholar 

  82. Krishna R, Ali M, Moustafa AA. Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson’s disease. Front Aging Neurosci. 2014;6:180.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  83. Biglan KM, Schwid S, Eberly S, Blindauer K, Fahn S, Goren T, et al. Rasagiline improves quality of life in patients with early Parkinson’s disease. Mov Disord. 2006;21(5):616–23.

    Article  PubMed  Google Scholar 

  84. Haycox A, Armand C, Murteira S, Cochran J, François C. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson’s disease in the UK setting: an economic Markov model evaluation. Drugs Aging. 2009;26(9):791–801.

    Article  PubMed  Google Scholar 

  85. Viallet F, Pitel S, Lancrenon S, Blin O. Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson’s disease. Curr Med Res Opin. 2013;29(1):23–31.

    Article  CAS  PubMed  Google Scholar 

  86. Stocchi F, Fossati C, Torti M. Rasagiline for the treatment of Parkinson’s disease: an update. Expert Opin Pharmacother. 2015;16(14):2231–41.

    Article  PubMed  CAS  Google Scholar 

  87. Kandadai RM, Jabeen SA, Kanikannan MA, Borgohain R. Safinamide for the treatment of Parkinson’s disease. Expert Rev Clin Pharmacol. 2014;7(6):747–59.

    Article  CAS  PubMed  Google Scholar 

  88. Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, et al. Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord. 2014;29(2):229–37.

    Article  CAS  PubMed  Google Scholar 

  89. Stocchi F, Torti M. Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide. Drug Des Devel Ther. 2016;10:609–18.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Devos D, Moreau C, Maltête D, Lefaucheur R, Kreisler A, Eusebio A, et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson’s disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry. 2014;85(6):668–74.

    Article  PubMed  Google Scholar 

  91. Mamikonyan E, Xie SX, Melvin E, Weintraub D. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. Mov Disord. 2015;30(7):912–8.

    Article  CAS  PubMed  Google Scholar 

  92. Witt K, Daniels C, Reiff J, Krack P, Volkmann J, Pinsker MO, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson’s disease: a randomised, multicentre study. Lancet Neurol. 2008;7(7):605–14.

    Article  PubMed  Google Scholar 

  93. Montel S, Bonnet A-M, Bungener C. Quality of life in relation to mood, coping strategies, and dyskinesia in Parkinson’s disease. J Geriatr Psychiatry Neurol. 2009;22(2):95–102.

    Article  PubMed  Google Scholar 

  94. Weaver FM, Follett KA, Stern M, Luo P, Harris CL, Hur K, et al. Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology. 2012;79(1):55–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Hariz G-M, Limousin P, Zrinzo L, Tripoliti E, Aviles-Olmos I, Jahanshahi M, et al. Gender differences in quality of life following subthalamic stimulation for Parkinson’s disease. Acta Neurol Scand. 2013;128(4):281–5.

    Article  PubMed  Google Scholar 

  96. Baláž M, Bočková M, Rektor I. DBS amplitude setting can improve aspects of quality of life in patients with Parkinson’s disease. J Neural Transm. 2013;120(4):643–8.

    Article  PubMed  Google Scholar 

  97. Clarke CE. Neuroprotection and pharmacotherapy for motor symptoms in Parkinson’s disease. Lancet Neurol. 2004;3(8):466–74.

    Article  PubMed  Google Scholar 

  98. Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L, et al. Duodenal levodopa infusion for advanced Parkinson’s disease: 12-month treatment outcome. Mov Disord. 2007;22(8):1145–9.

    Article  PubMed  Google Scholar 

  99. Pålhagen SE, Dizdar N, Hauge T, Holmberg B, Jansson R, Linder J, et al. Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease. Acta Neurol Scand. 2012;126(6):e29–33.

    Article  PubMed  CAS  Google Scholar 

  100. Meppelink AM, Nyman R, van Laar T, Drent M, Prins T, Leenders KL. Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson’s disease. Mov Disord. 2011;26(2):331–4.

    Article  PubMed  Google Scholar 

  101. Nyholm D, Nilsson Remahl AIM, Dizdar N, Constantinescu R, Holmberg B, Jansson R, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005;64(2):216–23.

    Article  CAS  PubMed  Google Scholar 

  102. Nyholm D, Constantinescu R, Holmberg B, Dizdar N, Askmark H. Comparison of apomorphine and levodopa infusions in four patients with Parkinson’s disease with symptom fluctuations. Acta Neurol Scand. 2009;119(5):345–8.

    Article  CAS  PubMed  Google Scholar 

  103. Isacson D, Bingefors K, Kristiansen IS, Nyholm D. Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion. Acta Neurol Scand. 2008;118(6):379–86.

    Article  CAS  PubMed  Google Scholar 

  104. Devos D. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease. Mov Disord. 2009;24(7):993–1000.

    Article  PubMed  Google Scholar 

  105. Santos-García D, Añón MJ, Fuster-Sanjurjo L, de la Fuente-Fernández R. Duodenal levodopa/carbidopa infusion therapy in patients with advanced Parkinson’s disease leads to improvement in caregivers’ stress and burden. Eur J Neurol. 2012;19(9):1261–5.

    Article  PubMed  Google Scholar 

  106. Santos-García D, Macías M, Llaneza M, Fuster-Sanjurjo L, Echarri-Piudo A, Belmonte S, et al. Experience with continuous levodopa enteral infusion (Duodopa(®)) in patients with advanced Parkinson’s disease in a secondary level hospital. Neurologia. 2010;25(9):536–43.

    Article  PubMed  Google Scholar 

  107. Santos-García D, Sanjurjo LF, Macías M, Llaneza M, Carpintero P, de la Fuente-Fernández R. Long-term exposure to duodenal levodopa/carbidopa infusion therapy improves quality of life in relation especially to mobility, activities of daily living, and emotional well-being. Acta Neurol Scand. 2012;125(3):187–91.

    Article  PubMed  CAS  Google Scholar 

  108. Zibetti M, Merola A, Ricchi V, Marchisio A, Artusi CA, Rizzi L, et al. Long-term duodenal levodopa infusion in Parkinson’s disease: a 3-year motor and cognitive follow-up study. J Neurol. 2013;260(1):105–14.

    Article  CAS  PubMed  Google Scholar 

  109. Castaño B, Mateo D, Giménez-Roldán S. Shifting to subcutaneous infusion of apomorphine in advanced Parkinson’s disease patients on an out-patient basis: experience and recommendations. Neurologia. 2007;22(3):133–7.

    PubMed  Google Scholar 

  110. Martinez-Martin P, Reddy P, Antonini A, Henriksen T, Katzenschlager R, Odin P, et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson’s disease compared to conventional therapy: a real life study of non motor effect. J Parkinsons Dis. 2011;1(2):197–203.

    CAS  PubMed  Google Scholar 

  111. Manson AJ, Hanagasi H, Turner K, Patsalos PN, Carey P, Ratnaraj N, et al. Intravenous apomorphine therapy in Parkinson’s disease clinical and pharmacokinetic observations. Brain. 2001;124(2):331–40.

    Article  CAS  PubMed  Google Scholar 

  112. Martinez-Martin P, Reddy P, Katzenschlager R, Antonini A, Todorova A, Odin P, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov Disord. 2015;30(4):510–6.

    Article  CAS  PubMed  Google Scholar 

  113. Drapier S, Eusebio A, Degos B, Vérin M, Durif F, Azulay JP, et al. Quality of life in Parkinson’s disease improved by apomorphine pump: the OPTIPUMP cohort study. J Neurol. 2016;263(6):1111–9.

    Article  CAS  PubMed  Google Scholar 

  114. Hauser RA. IPX066: a novel carbidopa-levodopa extended-release formulation. Expert Rev Neurother. 2012;12(2):133–40.

    Article  CAS  PubMed  Google Scholar 

  115. Dhall R, Kreitzman DL. Advances in levodopa therapy for Parkinson disease: review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Neurology. 2016;86(14 Suppl 1):S13–24.

    Article  CAS  PubMed  Google Scholar 

  116. Tomlinson CL, Patel S, Meek C, Herd CP, Clarke CE, Stowe R, et al. Physiotherapy intervention in Parkinson’s disease: systematic review and meta-analysis. BMJ. 2012;345:e5004.

    Article  PubMed  PubMed Central  Google Scholar 

  117. Rose MH, Løkkegaard A, Sonne-Holm S, Jensen BR. Improved clinical status, quality of life, and walking capacity in Parkinson’s disease after body weight-supported high-intensity locomotor training. Arch Phys Med Rehabil. 2013;94(4):687–92.

    Article  PubMed  Google Scholar 

  118. Tickle-Degnen L, Ellis T, Saint-Hilaire MH, Thomas CA, Wagenaar RC. Self-management rehabilitation and health-related quality of life in Parkinson’s disease: a randomized controlled trial. Mov Disord. 2010;25(2):194–204.

    Article  PubMed  PubMed Central  Google Scholar 

  119. Yousefi B, Tadibi V, Khoei AF, Montazeri A. Exercise therapy, quality of life, and activities of daily living in patients with Parkinson disease: a small scale quasi-randomised trial. Trials. 2009;10:67.

    Article  PubMed  PubMed Central  Google Scholar 

  120. Lauhoff P, Murphy N, Doherty C, Horgan NF. A controlled clinical trial investigating the effects of cycle ergometry training on exercise tolerance, balance and quality of life in patients with Parkinson’s disease. Disabil Rehabil. 2013;35(5):382–7.

    Article  PubMed  Google Scholar 

  121. da Silva FC, Iop Rda R, Dos Santos PD, Bezerra LM, Gutierres PJ, da Silva R. Effects of physical exercise based rehabilitation programs on quality of life in Parkinson’s disease patients: a systematic review of randomized controlled trials. J Aging Phys Act. 2016. [Epub ahead of print].

    Google Scholar 

  122. Ginis P, Nieuwboer A, Dorfman M, Ferrari A, Gazit E, Canning CG, et al. Feasibility and effects of home-based smartphone-delivered automated feedback training for gait in people with Parkinson’s disease: a pilot randomized controlled trial. Parkinsonism Relat Disord. 2016;22:28–34.

    Article  PubMed  Google Scholar 

  123. de Dreu MJ, van der Wilk ASD, Poppe E, Kwakkel G, van Wegen EEH. Rehabilitation, exercise therapy and music in patients with Parkinson’s disease: a meta-analysis of the effects of music-based movement therapy on walking ability, balance and quality of life. Parkinsonism Relat Disord. 2012;18 Suppl 1:S114–9.

    Article  PubMed  Google Scholar 

  124. Stegemöller EL, Radig H, Hibbing P, Wingate J, Sapienza C. Effects of singing on voice, respiratory control and quality of life in persons with Parkinson’s disease. Disabil Rehabil. 2016:1–7. doi:10.3109/09638288.2016.1152610.

  125. Serrano-Dueñas M, Serrano S. Psychometric characteristics of PIMS – compared to PDQ-39 and PDQL – to evaluate quality of life in Parkinson’s disease patients: validation in Spanish (Ecuadorian style). Parkinsonism Relat Disord. 2008;14(2):126–32.

    Article  PubMed  Google Scholar 

  126. Antonini A, Mancini F, Canesi M, Zangaglia R, Isaias IU, Manfredi L, et al. Duodenal levodopa infusion improves quality of life in advanced Parkinson’s disease. Neurodegener Dis. 2008;5(3–4):244–6.

    Article  CAS  PubMed  Google Scholar 

  127. Annic A, Devos D, Seguy D, Dujardin K, Destée A, Defebvre L. Continuous dopaminergic stimulation by Duodopa in advanced Parkinson’s disease: efficacy and safety. Rev Neurol (Paris). 2009;165(8–9):718–27.

    Article  CAS  Google Scholar 

  128. Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, et al. Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord. 2009;24(10):1468–74.

    Article  PubMed  Google Scholar 

  129. Puente V, De Fabregues O, Oliveras C, Ribera G, Pont-Sunyer C, Vivanco R, et al. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson’s disease: impact on control of fluctuations and quality of life. Parkinsonism Relat Disord. 2010;16(3):218–21.

    Article  CAS  PubMed  Google Scholar 

  130. Reddy P, Martinez-Martin P, Rizos A, Martin A, Faye GC, Forgacs I, et al. Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effects. Clin Neuropharmacol. 2012;35(5):205–7.

    Article  CAS  PubMed  Google Scholar 

  131. Foltynie T, Magee C, James C, Webster GJM, Lees AJ, Limousin P. Impact of duodopa on quality of life in advanced Parkinson’s disease: a UK case series. Parkinson’s Disease [Internet]. 2013. http://www.hindawi.com/journals/pd/2013/362908/abs/.

  132. Cáceres-Redondo MT, Carrillo F, Lama MJ, Huertas-Fernández I, Vargas-González L, Carballo M, et al. Long-term levodopa/carbidopa intestinal gel in advanced Parkinson’s disease. J Neurol. 2014;261(3):561–9.

    Article  PubMed  CAS  Google Scholar 

  133. Sensi M, Preda F, Trevisani L, Contini E, Gragnaniello D, Capone JG, et al. Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients. J Neural Transm. 2014;121(6):633–42.

    Article  CAS  PubMed  Google Scholar 

  134. Antonini A, Yegin A, Preda C, Bergmann L, Poewe W, GLORIA Study Investigators and Coordinators. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients; 12-month interim outcomes. Parkinsonism Relat Disord. 2015;21(3):231–5.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National School of Public Health, Carlos III Institute of Health and REDISSEC, C/ Monforte de Lemos 5, 28029, Madrid, Spain

    Maria João Forjaz

  2. National Center of Epidemiology, Carlos III Institute of Health and CIBERNED, C/ Monforte de Lemos 5, 28029, Madrid, Spain

    Carmen Rodriguez-Blazquez & Pablo Martinez-Martin

Authors
  1. Maria João Forjaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carmen Rodriguez-Blazquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pablo Martinez-Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria João Forjaz .

Editor information

Editors and Affiliations

  1. Faculty of Medicine, Transilvania University, Brasov, Romania

    Cristian Falup-Pecurariu

  2. Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, Lisbon, Portugal

    Joaquim Ferreira

  3. National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain

    Pablo Martinez-Martin

  4. Centre of Excellence, King’s College London, National Parkinson Foundation Centre of Excellence King’s College, London, United Kingdom

    Kallol Ray Chaudhuri

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag Wien

About this chapter

Cite this chapter

Forjaz, M.J., Rodriguez-Blazquez, C., Martinez-Martin, P. (2017). Quality of Life in Parkinson’s Disease. In: Falup-Pecurariu, C., Ferreira, J., Martinez-Martin, P., Chaudhuri, K. (eds) Movement Disorders Curricula. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1628-9_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-1628-9_16

  • Published:

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-1627-2

  • Online ISBN: 978-3-7091-1628-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation